MALAT1-mediated salvinorin A attenuates vascular endothelial damage in ischemic stroke
丁俊云,陈维英,王震虹,何振洲,张依爵
DOI: https://doi.org/10.3760/cma.j.cn321761-20200925-00163
2020-01-01
Abstract:Objective:To investigate the κ opioid receptor (KOR) agonist salvinorin A (SA) produced protective effects in ischemic stroke rats by upregulating long noncoding RNA (lncRNA) MALAT1 in cerebral vascular endothelial cells, inhibiting dynamin-related protein 1 (Drp-1) phosphorylation, and mitigating mitochondrial damage.Methods:Sixty male SD rats, weighed 200-250 g, were used for animal experiments and divided into four groups (15 rats each) according to random number table method. In the Sham group (S group), rats were isolated one side of the internal carotid artery without any intervention. In the middle cerebral artery occlusion model group (MCAO group), the rat carotid artery was blocked by wire embolus for 90 min, and the wire embolus was removed for reperfusion. In SA group, SA (20 μg/kg) was given via the tail vein immediately after internal carotid block. In the KOR antagonist group (NB group), norbinaltorphimine (norBIN 2 mg/kg) was given to rats 30 min before SA injection, and the rest of the treatment was the same as in the SA group. 24 h after MCAO, the degree of cerebral infarction in rats was assessed by Bederson score. After the execution, the rat cerebral infarct area was assessed by 2, 3, 5 Triphenyltertrazolium chloride (TTC), blood brain barrier permeability (Evans blue) were measured, and behavioral assessment and neural assessment (total motor score) was performed 1, 2 d and 5 d after MCAO. In vitro experiments were conducted using human brain microvascular endothelial cell (HBMEC) model of oxygenglucose deprivation (OGD) and divided into five groups: blank control group (Blank group), without OGD and reoxygenation; OGD group (group A), 6 h hypoxia, 24 h reoxygenation; SA+OGD group (group B), SA (5 μmol/L) was added 1 h before OGD model reoxygenation; MALAT1 specific small interfering RNA (siRNA)+OGD group (group C), 100 nmol/L lncRNA MALAT1 siRNA was added for 24 h, hypoxia for 6 h, and reoxygenation for 24 h; MALAT1 siRNA+OGD+SA group (group D), 100 nmol/L lncRNA MALAT1 siRNA was added for 24 h, 6 h of hypoxia, 24 h of reoxygenation, and SA was added 1 h before reoxygenation (5 μmol/L). The Cell Counting Kit8 (CCK8) was used to determine the activity of HBMEC, phosphorylated Drp-1 (pDrp-1)/Drp-1, reactive oxygen species (ROS) levels, and mitochondrial morphology was observed under electron microscope.Results:Animal experiments showed that, compared with S group, rats in MCAO group had significantly higher behavioral scores, significantly increased infarct size, significantly increased Envans blue exudation, and significantly decreased motor nerve function (
P<0.05). Compared with MCAO group, the behavioral scores of rats in the SA group were significantly lower, the infarct area was significantly reduced, Envans blue exudation was significantly reduced, and the motor nerve function of rats was significantly improved (
P<0.05). Compared with SA group, rats in NB group had significantly higher behavioral scores, larger infarct size, increased vascular permeability, and decreased neurological function (
P<0.05). In vitro experiments showed an increase in MALAT1 levels, a significant decrease in HBMEC activity, an increase in pDrp-1/Dpr-1 (
P<0.05), a significant increase in ROS content (
P<0.01), and mitochondrial morphological disruption visible under electron microscopy in group A compared with the Blank group. Compared with group A, group B had increased MALAT1 level, significantly increased HBMEC activity, decreased pDrp-1/Drp-1 (
P<0.05), significantly decreased ROS content (
P<0.01), and normalized mitochondrial morphology under electron microscope. Compared with group B, group C had significantly decreased HBMEC activity (
P<0.05), increased pDrp-1 /Drp-1, increased ROS content (
P<0.01) and disrupted mitochondrial morphology. Compared with group C, group D had significantly increased HBMEC activity and decreased pDrp-1/Drp-1 and ROS levels (
P<0.05), and the mitochondrial still had some degree of swelling.
Conclusions:The KOR agonist SA protects brain function after ischemic stroke by upregulating MALAT1 expression, attenuating mitochondrial damage in cerebral vascular endothelial cells after ischemic stroke, reducing oxidative stress in HBMEC, and reducing increased blood-brain.